We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Gelesis Holdings Inc | NYSE:GLS | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.1586 | 0 | 01:00:00 |
Gelesis (NYSE: GLS), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in two upcoming investor conferences:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518006013/en/
(Photo: Business Wire)
Wednesday, May 25, 2022: UBS Global Healthcare Conference: Gelesis will host a presentation beginning at 8:30 a.m. Eastern Time. The presentation will be webcast live here and on the Company’s investor relations website at ir.gelesis.com.
Wednesday, June 1, 2022: Third Annual Loop Capital Conference: Gelesis will participate virtually. Please contact your Loop Capital representative for further details.
About Gelesis
Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis”) is a consumer-centered biotherapeutics company and the maker of Plenity®, which is inspired by nature and FDA cleared to aid in weight management. Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks. They are inspired by the composition and mechanical properties of raw vegetables, taken by capsule, and act locally in the digestive system, so people feel satisfied with smaller portions. Our portfolio includes Plenity® and potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. For more information, visit gelesis.com, or connect with us on Twitter @GelesisInc.
Plenity® is indicated to aid weight management in adults with excess weight or obesity, a Body Mass Index (BMI) of 25–40 kg/m², when used in conjunction with diet and exercise.
Important Safety Information about Plenity
Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518006013/en/
Media & Investor Relations Katie Sullivan ksullivan@gelesis.com
1 Year Gelesis Chart |
1 Month Gelesis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions